Cancer:碳离子照射作为局部复发性鼻咽癌的挽救治疗,安全有效

2018-09-16 佚名 肿瘤资讯

局部复发性鼻咽癌的治疗手段较为有限,手术等其他治疗手段仅适用于小病灶肿瘤,大多数复发患者仍需接受再程放射治疗。然而,光子再程放疗的疗效有限,且毒性反应较高。上海市质子重离子医院头颈及中枢神经肿瘤科陆嘉德、孔琳教授团队潜心专研碳离子放射治疗复发性鼻咽癌技术逾3年,取得了较好的效果。通过多项研究,包括前瞻性I/II期临床研究及转化型研究,逐步确立了碳离子放射治疗局部复发性鼻咽癌的最佳技术、剂量和疗效。

局部复发性鼻咽癌的治疗手段较为有限,手术等其他治疗手段仅适用于小病灶肿瘤,大多数复发患者仍需接受再程放射治疗。然而,光子再程放疗的疗效有限,且毒性反应较高。上海市质子重离子医院头颈及中枢神经肿瘤科陆嘉德、孔琳教授团队潜心专研碳离子放射治疗复发性鼻咽癌技术逾3年,取得了较好的效果。通过多项研究,包括前瞻性I/II期临床研究及转化型研究,逐步确立了碳离子放射治疗局部复发性鼻咽癌的最佳技术、剂量和疗效。近期总结医院75例接受碳离子放疗患者的疗效和安全性,研究成果发表在美国癌症协会所属的国际知名期刊Cancer。

背景

对于非转移性鼻咽癌患者,放疗是唯一的根治手段。逐渐普及的光子调强放疗(IMRT)与同步放化疗策略可以显著改善患者的预后。然而,约10-15%的鼻咽癌患者在接受根治性IMRT后仍会出现局部复发。对于局部复发性鼻咽癌患者,再程放疗是最主要的挽救性治疗手段。手术、立体定向放疗和近距离照射等仅适用于复发病灶较小的患者,IMRT是目前对于任意分期(包括局部晚期疾病)的局部复发性鼻咽癌患者最有效的挽救性治疗方式。然而,高剂量的再程IMRT可能会引起严重的毒性反应,包括黏膜坏死、大出血、颅神经病变和脑坏死。有限的疗效及较高概率出现的致命性并发症,使得局部晚期(rT3/T4)复发性鼻咽癌患者接受再程IMRT治疗后的2年OS仅为40%左右。

碳离子射线的绝大部分能量沉积在射程尾端的布拉格峰区域。剂量学研究显示,碳离子调强放射治疗(IMCT)可将剂量精准投递至靶区,而对周围正常组织和脏器的影响较小,相比于IMRT,IMCT具有更高的治疗比。早期研究数据提示采用质子或重离子(非碳离子)放疗治疗局部复发性鼻咽癌是可行和潜在有效的。

同时,碳离子相比于光子和质子的相对生物效应比率为2-5:1。因此,相比基于光子的IMRT,IMCT具有物理学和生物学上的优势,采用碳离子调强放射治疗高剂量放疗后局部复发性鼻咽癌患者,可能可以进一步提高疾病控制率,并降低毒性反应。然而,IMCT治疗局部复发性鼻咽癌患者的潜在获益和毒性反应尚未在临床上进行过验证。本研究旨在总结报道IMCT治疗局部复发性鼻咽癌患者的早期疗效和安全性的初步数据。

方法

研究入组了在上海市质子重离子医院接受IMCT治疗的局部复发性鼻咽癌患者。所有患者均按照前瞻性方案接受碳离子调强放疗(距首次根治性光子放射治疗至少6个月)。治疗前的基线评估包括完整的病史采集和体格检查,间接鼻咽镜检查,血常规,血生化及心电图等。除非有临床禁忌,所有患者需进行MRI和全身PET/CT检测。对于合并远处转移的患者,仅当再程放疗可以改善其预后时方可入组。合并区域淋巴结转移的患者需要预评估是否可以进行颈清扫术。所有入组患者按照第七版AJCC分期系统对复发性疾病进行重新分期。

IMCT:患者接受调强碳离子放疗的总剂量及分割剂量根据所采用的治疗方案而不同。部分患者入组两项分割剂量为2.5GyE的I/II期剂量递增研究(伴或不伴同步化疗)中的一项,其初始剂量分别为55GyE和57.5GyE;部分患者入组分割剂量为3GyE的I/II期剂量递增研究,其初始剂量为54GyE;其余患者按照预先制定的标准治疗方案(SOP)接受IMCT,其剂量为50-66GyE(分割剂量为2.0 GyE/d,2.5 GyE/ d或3.0 GyE/ d)。1例局部复发性鼻咽癌患者的治疗计划见下图1. 

图1. 1例局部复发性鼻咽癌患者(rT3N0M0)的IMCT治疗计划

化疗:建议所有局部晚期的复发性鼻咽癌患者接受诱导化疗,但对化疗方案无强制要求。除入组IMCT结合同步化疗I/II期临床研究的患者需接受同步化疗外,IMCT期间不要求进行同步化疗。此外,也不要求进行辅助化疗。

随访:要求所有患者在完成IMCT后4-6周内至初诊医生门诊随访,之后前2年内每3个月随访1次,接下来3年每6个月随访1次,然后每年随访1次。每次随访进行完整的病史采集和体格检查,间接鼻咽镜检查以及头颈部MRI等。

疗效评价:OS定义为诊断局部复发至患者死亡或最后随访的时间;局部、区域无复发生存或无远处转移生存定义为诊断局部复发至出现相应的治疗失败的时间。采用RECIST标准评估治疗疗效。在开始IMCT 90天内出现的毒性反应定义为“急性”毒性反应;治疗相关的晚期毒性反应定义为在IMCT开始90天后出现的或持续时间>90天的毒性反应。

结果

1. 入组人群

2015年5月至2017年8月,共75例未经选择的局部复发性鼻咽癌(低分化或未分化鳞癌)患者在上海市质子重离子医院接受治疗。无患者合并远处转移。9例同时合并颈部淋巴结转移的患者在IMCT前接受颈部淋巴结清扫术,3例患者在IMCT后接受颈部淋巴结清扫术。所有纳入分析患者,其原发灶和淋巴结接受的初始放疗剂量为66-76Gy(28-38分次)。入组人群的特征总结见表1。除1例患者外(计划给予54GyE,2.0GyE/d;因担心治疗副作用,最终仅接受了50GyE的治疗剂量;IMCT治疗期间未观察到毒性作用),所有患者均按照计划完成IMCT治疗。 

共46例患者在IMCT前接受了1-6程的诱导化疗,化疗方案包括多西他赛联合顺铂,吉西他滨联合顺铂或5-FU联合顺铂。12例患者接受顺铂同步化疗,其中6例患者入组IMCT联合同步化疗的I/II期临床研究。

表1. 入组患者的基线特征



2. OS,局部、区域无复发生存、无远处转移生存和PFS分析

在中位随访15.4个月后,共有2例患者死亡,仅1例患者死亡与疾病治疗相关。1年OS率和疾病特异性生存(DSS)率均为98.1%,见图2。



图2. 接受IMCT治疗的局部复发性鼻咽癌患者的OS

截至本次分析,分别有21例、1例和2例患者出现局部复发、区域复发和远处转移。1年PFS率、局部无复发生存(LRFS)率、区域无复发生存(RRFS)率和无远处转移生存(DMFS)率分别为82.2%、86.6%、97.9%和96.2%,见图3。



图3. 接受IMCT治疗的局部复发性鼻咽癌患者的A.PFS; B. LRFS; C. RRFS和D. DMFS

3. 急性和晚期毒性反应

根治性IMRT治疗后局部复发的患者接受IMCT再程放疗的总体耐受性良好。在IMCT治疗期间或开始治疗后90天内,75例患者均未观察到>=2级的放疗相关的毒性反应。仅在9例患者中观察到与IMCT相关的急性毒性反应,为鼻咽/口咽黏膜1度红疹。无患者出现持续的脱发或皮肤红斑。7例患者在3个月随访后出现瘤床坏死,然而,在坏死瘤床周边的黏膜中未观察到坏死或红斑。晚期毒性反应的类型和发生率总结见下表2.

表2. 晚期毒性反应的类型和发生率



4. 局部和区域疾病控制的预测因子

将既往文献报道的影响局部复发性鼻咽癌患者IMRT再程放疗疗效的因素(除肿瘤体积外)进行单因素和多因素分析,包括年龄,性别,复发时的疾病分期,至疾病复发间隔时间,诱导和或同步化疗的应用,再程IMCT的总剂量,分割剂量和生物等效剂量(BED)。因本研究队列中仅2例患者死亡,仅1例患者因治疗相关因素死亡,因此,未进行OS和疾病特异性生存的分析。

采用log-rank检验进行单因素分析,结果见表3。分割剂量(<3GyE vs. 3GyE)和BED(<74.1GyE vs. >=74.1GyE)可以显著预测PFS(P值分别为0.027和0.035),见图4。采用Cox回归进行针对PFS的单因素和多因素分析(表4和5),在单因素分析中,分割剂量(HR 0.27;P=0.039)和BED(HR 0.91;P=0.031)均和PFS显著相关;但在多因素分析中无统计学意义。



图4. 接受IMCT治疗的局部复发的鼻咽癌患者PFS的分层分析:A. 剂量分割;B. BED

表3. 采用K-M法进行单因素分析



表4. Cox回归模型进行PFS单因素分析



表5. PFS多因素分析



结论

采用IMCT治疗局部复发性鼻咽癌是安全有效的,在中位随访15.4个月后,1年OS,DSS,PFS,LRFS,RRFS和DMFS率分别为98.1%,98.1%,82.2%,86.6%,97.9%和96.2%。所有患者均未观察到严重急性毒性反应,而晚期毒性反应发生率也较低。仍需进行更长时间的随访以进一步探寻最佳总剂量和分割剂量,并观察患者的长期结局和晚期毒性。

点评

鼻咽癌是中国常见的头颈部恶性肿瘤,放射治疗是其最重要的根治性手段。随着调强放射治疗(IMRT)技术和联合化疗的广泛应用,目前鼻咽癌患者的长期生存有了长足提高,非转移性鼻咽癌患者的5年总生存率已接近90%,但仍有约10-15%的患者在根治性放疗后可能出现局部复发。局部复发鼻咽癌的治疗手段较为有限,手术等仅适用于小病灶肿瘤,大多数复发患者仍需接受放射治疗。然而,根治性放疗后的复发肿瘤往往放射敏感性差,且首次放疗对肿瘤周围的重要正常器官和组织的照射,使得再程放射治疗后的毒性反应远高于首次治疗。因此,采用常规光子再程放射治疗局部复发性鼻咽癌的疗效不佳。复旦大学附属肿瘤医院发表的数据显示,局部复发性鼻咽癌患者接受再程IMRT后,3年生存率仅50%左右,且严重晚期毒性反应发生率高,约65%的患者出现治疗相关的鼻咽黏膜溃疡大出血、放射性脑坏死等重度毒副作用,死亡患者中超过一半的患者是因为严重毒性反应所致。

上海市质子重离子医院头颈及中枢神经肿瘤科陆嘉德、孔琳教授团队潜心专研碳离子射线放射治疗复发性鼻咽癌技术逾3年,取得了较好的疗效。首先在物理剂量学上证实了碳离子放射技术优于光子精准调强放射治疗,并在上海申康医院发展中心新兴前沿技术基金等项目的支持下,通过多项前瞻性I/II期临床研究、转化型研究,逐步确立了碳离子射线放射治疗局部复发鼻咽癌的最佳技术、剂量和疗效。根据团队最近总结的医院75例患者接受治疗后的结果显示,局部复发鼻咽癌采用碳离子射线放射治疗效果喜人:患者的1年总生存率高达98.2%;严重毒副反应的发生率不超过10%。良好的结果改写了局部复发鼻咽癌再程放射治疗的疗效,该研究成果发表在美国癌症协会所属的国际知名期刊Cancer今年六月号,意味该技术获得了国际专家同行的认可。目前通过碳离子射线放疗技术获益的复发鼻咽癌患者已超过百人。疗效获得了进一步验证。

上海市质子重离子医院头颈及中枢神经肿瘤团队在鼻咽癌治疗领域获得了良好疗效的同时,进一步开展了旨在攻克难治性头颈部肿瘤的多个研究项目。目前碳离子射线治疗复发头颈部恶性肿瘤(非鼻咽癌)、头颈部肉瘤、眼眶肿瘤及鼻腔鼻窦恶性肿瘤等研究均已获得了良好的成果。

原始出处:
Hu J, Bao C, Gao J, Guan X, Hu W, Yang J, Hu C, Kong L, Lu JJ. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results. Cancer. 2018 Jun 1;124(11):2427-2437.   

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
    2018-09-18 chg122
  5. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
    2018-09-17 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
    2018-09-16 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
    2018-09-16 王秀

    学习了,涨知识了!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1928282, encodeId=a18419282824a, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Feb 18 19:32:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060547, encodeId=2821206054e94, content=<a href='/topic/show?id=1daf42566e7' target=_blank style='color:#2F92EE;'>#复发性鼻咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42566, encryptionId=1daf42566e7, topicName=复发性鼻咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 26 08:32:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Mar 22 01:32:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405858, encodeId=4fb51405858d1, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487832, encodeId=c77c148e8322a, content=<a href='/topic/show?id=46385651633' target=_blank style='color:#2F92EE;'>#挽救治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56516, encryptionId=46385651633, topicName=挽救治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a8374760, createdName=drwjr, createdTime=Tue Sep 18 12:32:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345373, encodeId=378f3453e3d7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 17 16:48:53 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345279, encodeId=681e3452e93e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Sep 16 22:16:05 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345276, encodeId=bd4a3452e68b, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Sep 16 22:11:27 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345272, encodeId=04dd3452e2d1, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sun Sep 16 21:52:42 CST 2018, time=2018-09-16, status=1, ipAttribution=)]
    2018-09-16 lofter

    学习了感谢分享

    0